# Literature-inject drugs for atherosclerosis origin-disease reassessment.
# These are clinically important drugs with published trial evidence
# that may not appear in the KG-derived V3 ranking.
#
# Format: name (lowercase canonical), endpoint_type, optional note.
# endpoint_type: CV_EVENTS | PLAQUE_IMAGING | LIPID | INFLAMMATION | OTHER

- name: colchicine
  endpoint_type: CV_EVENTS
  note: "COLCOT/LoDoCo2 — MACE reduction, FDA 2023"

- name: canakinumab
  endpoint_type: CV_EVENTS
  note: "CANTOS — anti-IL-1β, MACE reduction"

- name: methotrexate
  endpoint_type: CV_EVENTS
  note: "CIRT — anti-inflammatory, negative result"

- name: losmapimod
  endpoint_type: PLAQUE_IMAGING
  note: "p38 MAPK inhibitor, plaque imaging endpoints"

- name: evolocumab
  endpoint_type: CV_EVENTS
  note: "FOURIER — PCSK9 inhibitor, LDL + CV events"

- name: tocilizumab
  endpoint_type: CV_EVENTS
  note: "Anti-IL-6R, cardiovascular inflammation"
